Abstract
Author(s): Belma Gözde Özdemir*, Feyza Duran, Leyla Aghakishiyeva, Betül Dik, Burcu Gezer Yurteri, Emine Aslanlar, Ahmet Bilgi, Çetin Çelik
Background/Aim: Tranexamic acid is a drug that controls bleeding by affecting fibrinolytic pathways. This study investigated the effect of routine use of Tranexamic Acid (TXA) on blood loss in gynecologic oncology surgeries.
Materials and methods: 160 gynecologic oncology patients who underwent surgery at the Department of Obstetrics and Gynecology at Selçuk University between 2023 and 2024 were evaluated. Patients were divided into two groups: those who received TXA (n=80) and those who did not (n=80). TXA was administered intravenously at a dose of 1 gram intraoperatively.
Results: A significant reduction in drain fluid volume was observed in the TXA group. While the postoperative decrease in hemoglobin levels was substantial in both groups, the TXA group had more stable values. Although blood loss decreased, the difference was not statistically significant. No complications such as thrombus were observed. Liver enzymes (ALT, AST) increased postoperatively in both groups. Surgery duration was slightly prolonged in the TXA group.
Conclusion: TXA was effective in controlling bleeding and reducing drain fluid output in gynecologic oncology surgery, but did not cause significant changes in laboratory parameters. It was concluded that TXA is a safe and beneficial agent when used at an appropriate dose and with proper patient selection. However, larger-scale, multicenter studies are needed.